Ann: 2021 Results - a transformational year for Neuren, page-56

Davis' words about Acadia shed light on some aspects that we've been thinking about for some time now. Davis clearly states that Acadia will pursue the improvement of therapy for the righteous community through Stoke, which will not only provide the opportunity for innovative experimentation, but will offer Acadia a Rett therapy, which can be offered exclusively for the world market. which he reiterates is not for Trofinetide, which is exclusive to North America alone. this is a fundamental step, because in In addition to Trofinetide in FX option. it is clear that at some point Acadia and Neuren will be direct competitors on the Rett primis and perhaps others who will advance respectively with 2591 and Spoke. the two companies are evidently divergent in a vision of the future; this suggests that Acadia has long been aware that Neuren has a partner or in More, it will necessarily be supported by a large cap biotechnology. in operational terms and in compliance with New Zealand rules, first of all I consider realistic, an entry into a large biotechnology other than Acadia into the capital at 20% for the direct allocation of shares at a multiple price of $ 2 (my research leads to Pizer / Roche) at the launch of phase 2 of Pra